SYSTM Wealth Solutions LLC Has $2.86 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

SYSTM Wealth Solutions LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 10.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,201 shares of the medical device company’s stock after acquiring an additional 2,344 shares during the quarter. SYSTM Wealth Solutions LLC’s holdings in DexCom were worth $2,857,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of DXCM. Gilbert & Cook Inc. boosted its holdings in shares of DexCom by 8.2% during the 4th quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock valued at $426,000 after acquiring an additional 261 shares in the last quarter. 9258 Wealth Management LLC acquired a new stake in shares of DexCom during the 4th quarter valued at $286,000. Dimensional Fund Advisors LP boosted its holdings in shares of DexCom by 6.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 647,172 shares of the medical device company’s stock valued at $80,308,000 after acquiring an additional 39,786 shares in the last quarter. Avantax Advisory Services Inc. acquired a new stake in shares of DexCom during the 4th quarter valued at $330,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of DexCom during the 4th quarter valued at $284,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DexCom news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the sale, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,483 shares of company stock valued at $201,708. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $145.00 target price on shares of DexCom in a report on Tuesday, July 23rd. Oppenheimer cut their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Barclays cut their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Finally, Baird R W downgraded DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Stock Performance

Shares of DexCom stock opened at $68.94 on Wednesday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market capitalization of $27.42 billion, a price-to-earnings ratio of 44.48, a PEG ratio of 2.12 and a beta of 1.18. The business has a 50-day simple moving average of $80.70 and a 200 day simple moving average of $110.54. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the previous year, the company posted $0.34 EPS. The firm’s revenue was up 15.3% compared to the same quarter last year. On average, research analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.